aidsВИЧ-инфекция и иммуносупрессииHIV Infection and Immunosuppressive Disorders2077-9828Baltic Medical Education Center10.22328/2077-9828-2023-15-3-105-115aids-830Research ArticleНОВЫЕ ТЕХНОЛОГИИNEW TECHNOLOGIESОценка медицинских технологий при COVID-19Medical technologies assessment in COVID-19https://orcid.org/0000-0002-1919-2909КолбинА. С.KolbinA. S.

Колбин Алексей Сергеевич — доктор медицинских наук, профессор, заведующий кафедрой клинической фармакологии и доказательной медицины; профессор кафедры фармакологии, медицинского факультета

197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8;

199034, Санкт-Петербург, Университетская наб., д. 7–9

 

St. Petersburg

Alex.kolbin1971@gmail.comГомонЮ. М.GomonYu. M.

Гомон Юлия Михайловна — доктор медицинских наук, профессор кафедры клинической фармакологии и доказательной медицины

197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8.

St. Petersburg

Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Санкт-Петербургский государственный университетРоссияPavlov First St. Petersburg State Medical University; St. Petersburg State UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссияPavlov First St. Petersburg State Medical UniversityRussian Federation202321102023153105115Copyright © Колбин А.С., Гомон Ю.М., 20232023Колбин А.С., Гомон Ю.М.Kolbin A.S., Gomon Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hiv.bmoc-spb.ru/jour/article/view/830

Согласно официальной информации о коронавирусе на май 2023 г. в России от COVID-19 умерло около 400 тыс. человек, в мире — 6,9 млн человек. С пандемией COVID-19 ассоциированы социальные, медицинские и экономические аспекты. Основные глобальные финансовые ресурсы были направлены на обеспечение вакцинами ($13,8 млрд, 40,4%); реорганизацию систем здравоохранения ($4,1 млрд); лекарственную терапию COVID-19 ($3,4 млрд). Затраты на научные исследования, разработку и изучение вакцин и лекарств составили только 0,6% общих затрат ($166 млн). В статье представлен клинико-фармакологический анализ различных лекарств, рекомендуемых для лечения инфекции. Дано обоснование, почему надежность и эффективность национальных систем оценки технологий здравоохранения приобрели особую актуальность.

According to official information about the coronavirus, as of May 2023, about 400 thousand people died from COVID-19 in Russia, 6.9 million people in the world. Social, as well as medical and economic aspects are associated with the COVID-19 pandemic. The main global financial resources were allocated to the provision of vaccines ($13.8 billion, 40.4%); reorganization of health systems ($4.1 billion); COVID-19 drug therapy ($3.4 billion). The costs of research, development and study of vaccines and medicines accounted for only 0.6% of total costs ($166 million). The article presents a clinical and pharmacological analysis of various medicines recommended for the treatment of infection. In these conditions, the reliability and effectiveness of national health technology assessment systems has become particularly relevant.

оценка технологий здравоохраненияданные реальной клинической практикиCOVID-19бремя болезнилекарстваhealth technology assessmentreal-world dataCOVID-19burden of diseasemedicinesReferencesThe international network of agencies for health technology assessment (INAHTA). https://www.inahta.org/The international network of agencies for health technology assessment (INAHTA). https://www.inahta.org/Курылёв А.А., Журавков А.А., Колбин А.С. Реальная клиническая практика при оценке технологий здравоохранения: состояние на 2022 год // Реальная клиническая практика: данные и доказательства. 2022. Т. 4, № 3. С. 1–9. https://doi.org/10.37489/2782-3784-myrwd-21.Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Real clinical practice in the assessment of healthcare technologies: the state for 2022. Real clinical practice: data and evidence. 2022, Vol. 4, No. 3, рр. 1–9 (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-21.Федеральный закон «Об обращении лекарственных средств» oт 12.04.2010 № 61-ФЗ (ред. от 26.03.2022). Статья 4. Основные понятия, используемые в настоящем Федеральном законе, и Статья 60. Государственное регулирование цен на лекарственные препараты для медицинского применения.Federal Law «On Circulation of Medicines» dated 12.04.2010 No. 61-FZ (ed. dated 26.03.2022). Article 4. The basic concepts used in this Federal Law and Article 60. State regulation of prices for medicines for medical use (In Russ.)Nordon C., Karcher H., Groenwold R.H. et al.; GetReal consortium. The «Efficacy-Effectiveness Gap»: Historical Background and Current Conceptualization // Value Health. 2016. Vol. 19, No. 1. Р. 75–81. doi: 10.1016/j.jval.2015.09.2938.Nordon C., Karcher H., Groenwold R.H. et al.; GetReal consortium. The «Efficacy-Effectiveness Gap»: Historical Background and Current Conceptualization // Value Health. 2016. Vol. 19, No. 1. Р. 75–81. doi: 10.1016/j.jval.2015.09.2938.Колбин А.С. и др. Исследования реальной клинической практики. М.: Изд-во ОКИ: Буки Веди, 2020. 208 с.: ил. ISBN 978-5-4465-2902-5.Kolbin A.S. et al. Research of real clinical practice. Moscow: OKI Publishing House: Buki Vedi, 2020. 208 p.: ill. (In Russ.) ISBN 978-5-4465-2902-5.Вербицкая Е.В. Доказательная медицина: основные понятия, принципы поиска и оценки информации: методическое пособие / под ред. А.С. Колбина. СПб.: РИЦ ПСПбГМУ, 2017. 36 с.Verbitskaya E.V. Evidence-based medicine: basic concepts, principles of information search and evaluation: a methodological guide / ed. by A.S. Kolbin. St. Petersburg: RIC PSPbSMU, 2017. 36 p. (In Russ.)Leahy J. et al. Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group // Value Health. 2020. Nov; Vol. 23, No. 11. Р. 1423–1426. doi: 10.1016/j.jval.2020.09.003.Leahy J. et al. Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group // Value Health. 2020. Nov; Vol. 23, No. 11. Р. 1423–1426. doi: 10.1016/j.jval.2020.09.003.Institute for Health Metrics and Evaluation (IHME): global burden of disease. https://www.healthdata.org/gbd.Institute for Health Metrics and Evaluation (IHME): global burden of disease. https://www.healthdata.org/gbd.Institute for Health Metrics and Evaluation (IHME): news. https://www.healthdata.org/news-release/covid-19-has-caused-69-million-deathsglobally-more-double-what-official-reports-show.Institute for Health Metrics and Evaluation (IHME): news. https://www.healthdata.org/news-release/covid-19-has-caused-69-million-deathsglobally-more-double-what-official-reports-show.CORONAVIRUS (COVID-19). Информационный портал [CORONAVIRUS (COVID-19). Information portal (In Russ.)]. https://coronavirusmonitorus.ru.CORONAVIRUS (COVID-19). Информационный портал [CORONAVIRUS (COVID-19). Information portal (In Russ.)]. https://coronavirusmonitorus.ru.Institute for Health Metrics and Evaluation (IHME) https://www.healthdata.org/infographic/fgh-2021-covid-19.Institute for Health Metrics and Evaluation (IHME) https://www.healthdata.org/infographic/fgh-2021-covid-19.Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Marc L. Berger International Society for Pharmacoeconomics and Outcomes Research, 2003. 264 р.Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Marc L. Berger International Society for Pharmacoeconomics and Outcomes Research, 2003. 264 р.Колбин А.С., Гомон Ю.М. Социально-экономическое и глобальное бремя COVID-19. // Беляков Н.А., Багненко С.Ф., Рассохин В.В. и др. Эволюция пандемии COVID-19: монография. СПб.: Балтийский медицинский образовательный центр, 2021. С. 349–359. ISBN 978-5-6041808-8-4.Kolbin A.S., Gomon Y.M. Socio-economic and global burden of COVID-19 // Belyakov N.A., Bagnenko S.F., Rassokhin V.V. et al. The evolution of the COVID19 pandemic: a monograph. St. Petersburg: Baltic Medical Educational Center, 2021, рр. 349–359 (In Russ.) ISBN 978-5-6041808-8-4.Колбин А.С. Ранняя оценка эффективности лекарственных средств при лечении больных с COVID-19 // Инфекция и иммунитет. 2020. Т. 10, № 2. С. 277–286Kolbin A.S., Gomon Y.M. Socio-economic and global burden of COVID-19 // Belyakov N.A., Bagnenko S.F., Rassokhin V.V. et al. The evolution of the COVID19 pandemic: a monograph. St. Petersburg: Baltic Medical Educational Center, 2021, рр. 349–359 (In Russ.)Zhou H., Fang Y., Xu T. et al. Potential therapeutic targets and promising drugs for combating SARS-CoV-2 // Br. J. Pharmacol. 2020. Vol. 177, No. 14. Р. 3147–3161. doi: 10.1111/bph.15092.Zhou H., Fang Y., Xu T. et al. Potential therapeutic targets and promising drugs for combating SARS-CoV-2 // Br. J. Pharmacol. 2020. Vol. 177, No. 14. Р. 3147–3161. doi: 10.1111/bph.15092.Khan E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review // J. Clin. Pharmacol. 2021. Vol. 61, No. 4. Р. 429–460. doi: 10.1002/jcph.1822.Khan E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review // J. Clin. Pharmacol. 2021. Vol. 61, No. 4. Р. 429–460. doi: 10.1002/jcph.1822.Колбин А.С. Фармакотерапия COVID-19 с позиций доказательной медицины // Беляков Н.А., Багненко С.Ф., Рассохин В.В. и др. Эволюция пандемии COVID-19: монография. СПб.: Балтийский медицинский образовательный центр, 2021. С. 287–311. ISBN 978-5-6041808-8-4.Kolbin A.S. Pharmacotherapy COVID-19 from the standpoint of evidence-based medicine. Belyakov N.A., Bagnenko S.F., Rassokhin V.V. et al. The evolution of the COVID-19 pandemic: a monograph. St. Petersburg: Baltic Medical Educational Center, 2021, рр. 287–311 (In Russ.) ISBN 978-5-6041808-8-4.Колбин А.С. COVID-19 и клиническая фармакология // Клиническая фармакология и терапия. 2020. Т. 29, № 3. С. 1–11. doi: 10.32756/0869- 5490-2020-3.Kolbin A.S. COVID-19 and clinical pharmacology. Clinical Pharmacology and Therapy, 2020, Vol. 29, No. 3, рр. 1–11 (In Russ.) doi: 10.32756/0869- 5490-2020-3.Peng F., Tu L., Yang Y., Hu P., Wang R., Hu Q. et al. Management and Treatment of COVID-19: The Chinese Experience // Can. J. Cardiol. 2020. Vol. 36, No. 6. Р. 915–930. doi: 10.1016/j.cjca.2020.04.010.Peng F., Tu L., Yang Y., Hu P., Wang R., Hu Q. et al. Management and Treatment of COVID-19: The Chinese Experience // Can. J. Cardiol. 2020. Vol. 36, No. 6. Р. 915–930. doi: 10.1016/j.cjca.2020.04.010.Клиническое ведение тяжелой острой респираторной инфекции при подозрении на новую коронавирусную (2019-nCoV) инфекцию. Временные рекомендации 28 января 2020 г. ВОЗ. https://apps.who.int/iris/bitstream/handle/10665/330893/WHO-nCoV-Clinical-2020.3-rus.pdfClinical management of severe acute respiratory infection with suspected new coronavirus (2019-nCoV) infection. Interim recommendations January 28, 2020 IT WILL INCREASE. (In Russ.) https://apps.who.int/iris/bitstream/handle/10665/330893/WHO-nCoV-Clinical-2020.3-rus.pdfWHO Solidarity Trial Consortium. et al. Repurposed Antiviral Drugs for COVID-19 — Interim WHO Solidarity Trial Results // N. Engl. J. Med. 2021. Vol. 384, No. 6. Р. 497–511. doi: 10.1056/NEJMoa2023184.WHO Solidarity Trial Consortium. et al. Repurposed Antiviral Drugs for COVID-19 — Interim WHO Solidarity Trial Results // N. Engl. J. Med. 2021. Vol. 384, No. 6. Р. 497–511. doi: 10.1056/NEJMoa2023184.Siemieniuk R., Bartoszko J.J., Ge L., Zeraatkar D., Izcovich A., Kum E. et al. Drug treatments for COVID-19: living systematic review and network meta-analysis (Update 2) // BMJ. 2020. Vol. 370. m2980.Siemieniuk R., Bartoszko J.J., Ge L., Zeraatkar D., Izcovich A., Kum E. et al. Drug treatments for COVID-19: living systematic review and network meta-analysis (Update 2) // BMJ. 2020. Vol. 370. m2980.Министерство здравоохранения Российской Федерации. Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции 2019-nCoV. Версия 1 (29.01.20) https://www.rosminzdrav.ru/news/2020/01/30/13236-vremennye-metodicheskie-rekomendatsii-po-profilaktike-diagnostike-i-lecheniyunovoy-koronavirusnoy-infektsii-2019-ncovMinistry of Health of the Russian Federation. Temporary guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019-nCoV. Version 1 (29.01.20) (In Russ.) https://www.rosminzdrav.ru/news/2020/01/30/13236-vremennye-metodicheskie-rekomendatsii-po-profilaktike-diagnostike-i-lecheniyunovoy-koronavirusnoy-infektsii-2019-ncovПостановление Правительства РФ от 2 июля 2020 г. № 973 «Об особенностях организации оказания медицинской помощи при угрозе распространения заболеваний, представляющих опасность для окружающих» https://www.garant.ru/products/ipo/prime/doc/74247048/Decree of the Government of the Russian Federation No. 973 dated July 2, 2020 «On the specifics of the organization of medical care in case of the threat of the spread of diseases that pose a danger to others» (In Russ.) https://www.garant.ru/products/ipo/prime/doc/74247048/EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19. ClinicalTrials.gov Identifier: NCT04960202. https://clinicaltrials.gov/ct2/show/NCT04960202?term=NCT04960202&draw=2&rank=1.EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19. ClinicalTrials.gov Identifier: NCT04960202. https://clinicaltrials.gov/ct2/show/NCT04960202?term=NCT04960202&draw=2&rank=1.Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html.Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html.Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 16 (18.08.2022) https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf.Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Version 16 (08/18/2022) (In Russ.) https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf.A living WHO guideline on drugs for COVID-19 // BMJ. 2020. Vol. 370. m3379. https://www.bmj.com/content/370/bmj.m3379.A living WHO guideline on drugs for COVID-19 // BMJ. 2020. Vol. 370. m3379. https://www.bmj.com/content/370/bmj.m3379.Reis S., Metzendorf M.I., Kuehn R. et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 // Cochrane Database Syst. Rev. 2022. Vol. 9, No. 9. CD015395. doi: 10.1002/14651858.CD015395.pub2.Reis S., Metzendorf M.I., Kuehn R. et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 // Cochrane Database Syst. Rev. 2022. Vol. 9, No. 9. CD015395. doi: 10.1002/14651858.CD015395.pub2.Dal-Ré R. et al. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach // Lancet Infect. Dis. 2022. Vol. 22. e231–38 https://doi.org/10.1016/S1473-3099(22)00119-0.Dal-Ré R. et al. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach // Lancet Infect. Dis. 2022. Vol. 22. e231–38 https://doi.org/10.1016/ S1473-3099(22)00119-0.Penman S. et al. Safety perspectives on presently considered drugs for the treatment of COVID-19 // Br. J. Pharmacol. 2020. Vol. 177, No. 19. Р. 4353–4374. doi: 10.1111/bph.15204.Penman S. et al. Safety perspectives on presently considered drugs for the treatment of COVID-19 // Br. J. Pharmacol. 2020. Vol. 177, No. 19. Р. 4353–4374. doi: 10.1111/bph.15204.Grundeis F, Ansems K, Dahms K et al. Remdesivir for the treatment of COVID-19 // Cochrane Database Syst Rev. 2023. Vol. 1(1. CD014962. doi: 10.1002/14651858.CD014962.pub2.Grundeis F, Ansems K, Dahms K et al. Remdesivir for the treatment of COVID-19 // Cochrane Database Syst Rev. 2023. Vol. 1(1. CD014962. doi: 10.1002/14651858.CD014962.pub2.Brophy J.M. Molnupiravir’s authorisation was premature // BMJ. 2022. Vol. 376. o443. doi: 10.1136/bmj.o443.Brophy J.M. Molnupiravir’s authorisation was premature // BMJ. 2022. Vol. 376. o443. doi: 10.1136/bmj.o443.Callaway E. COVID drug drives viral mutations — and now some want to halt its use // Nature. 2023. Vol. 614, No. 7948. Р. 399. doi: 10.1038/d41586-023-00347-z.Callaway E. COVID drug drives viral mutations — and now some want to halt its use // Nature. 2023. Vol. 614, No. 7948. Р. 399. doi: 10.1038/d41586-023-00347-z.Shapiro A., Ignacio B. Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 // Lancet Infect Dis. 2021. S1473-3099(21)00762-3. doi: 10.1016/S1473-3099(21)00762-3. Online ahead of print.Shapiro A., Ignacio B. Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 // Lancet Infect Dis. 2021. S1473-3099(21)00762-3. doi: 10.1016/S1473-3099(21)00762-3. Online ahead of print.Boskovic M., Migo W., Likic R. SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? // Br. J. Clin. Pharmacol. 2021. Vol. 87, No. 11. Р. 4476–4478. doi: 10.1111/bcp.14849.Boskovic M., Migo W., Likic R. SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? // Br. J. Clin. Pharmacol. 2021. Vol. 87, No. 11. Р. 4476–4478. doi: 10.1111/bcp.14849.Greaney А. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies // Cell Host Microbe. 2021. Vol. 29, No. 3. Р. 463–476.e6. doi: 10.1016/j.chom.2021.02.003.Greaney А. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies // Cell Host Microbe. 2021. Vol. 29, No. 3. Р. 463–476.e6. doi: 10.1016/j.chom.2021.02.003.Hirsch C., Park Y.S., Piechotta V. et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19 // Cochrane Database Syst Rev. 2022. Vol. 6, No. 6. CD014945. doi: 10.1002/14651858.CD014945.pub2.Hirsch C., Park Y.S., Piechotta V. et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19 // Cochrane Database Syst Rev. 2022. Vol. 6, No. 6. CD014945. doi: 10.1002/14651858.CD014945.pub2.Ghosn L., Assi R., Evrenoglou T. et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review // Cochrane Database Syst. Rev. 2023. Vol. 6, No. 6. CD013881. doi: 10.1002/14651858.CD013881.pub2.Ghosn L., Assi R., Evrenoglou T. et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review // Cochrane Database Syst. Rev. 2023. Vol. 6, No. 6. CD013881. doi: 10.1002/14651858.CD013881.pub2.Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020) http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/MR_COVID-19_v7.pdfTemporary methodological recommendations prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 7 (03.06.2020) (In Russ.) http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/MR_COVID-19_v7.pdfWagner C., Griesel M., Mikolajewska A. et al. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence // Cochrane Database Syst. Rev. 2022. Vol. 11(11. CD014963. doi: 10.1002/14651858.CD014963.pub2.Wagner C., Griesel M., Mikolajewska A. et al. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence // Cochrane Database Syst. Rev. 2022. Vol. 11(11. CD014963. doi: 10.1002/14651858.CD014963.pub2.Kramer A., Prinz C., Fichtner F. et al. Janus kinase inhibitors for the treatment of COVID-19 // Cochrane Database Syst. Rev. 2022. Vol. 6, No. 6. CD015209. doi: 10.1002/14651858.CD015209.Kramer A., Prinz C., Fichtner F. et al. Janus kinase inhibitors for the treatment of COVID-19 // Cochrane Database Syst. Rev. 2022. Vol. 6, No. 6. CD015209. doi: 10.1002/14651858.CD015209.Cox M. et al. Co-infections: potentially lethal and unexplored in COVID-19 // The Lancet Microbe. 2020. Vol. 1, No. 1. e11. doi: 10.1016/S2666- 5247(20)30009-4.Cox M. et al. Co-infections: potentially lethal and unexplored in COVID-19 // The Lancet Microbe. 2020. Vol. 1, No. 1. e11. doi: 10.1016/S2666- 5247(20)30009-4.Langford B.J. et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis // Lancet Microbe. 2023. Vol. 4, No. 3. e179-e191. doi: 10.1016/S2666 5247(22)00355-X.Langford B.J. et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis // Lancet Microbe. 2023. Vol. 4, No. 3. e179-e191. doi: 10.1016/S2666 5247(22)00355-X.

The authors declare that there are no conflicts of interest present.